Equillium Inc
NASDAQ:EQ

Watchlist Manager
Equillium Inc Logo
Equillium Inc
NASDAQ:EQ
Watchlist
Price: 0.7549 USD -3.22% Market Closed
Market Cap: 26.7m USD

Equillium Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Equillium Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Equillium Inc
NASDAQ:EQ
Net Income (Common)
-$4.6m
CAGR 3-Years
50%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$4.2B
CAGR 3-Years
-28%
CAGR 5-Years
-12%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$480m
CAGR 3-Years
-57%
CAGR 5-Years
-38%
CAGR 10-Years
-28%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.1B
CAGR 3-Years
-11%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$535.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
3%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.4B
CAGR 3-Years
-18%
CAGR 5-Years
16%
CAGR 10-Years
29%

Equillium Inc
Glance View

Market Cap
26.7m USD
Industry
Biotechnology

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.

EQ Intrinsic Value
0.847 USD
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Equillium Inc's Net Income (Common)?
Net Income (Common)
-4.6m USD

Based on the financial report for Sep 30, 2024, Equillium Inc's Net Income (Common) amounts to -4.6m USD.

What is Equillium Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
27%

Over the last year, the Net Income (Common) growth was 44%. The average annual Net Income (Common) growth rates for Equillium Inc have been 50% over the past three years , 27% over the past five years .

Back to Top